Education & Training

Medical School

Kochi Medical School

Internship

Internal Medicine

  • Beth Israel Medical Center

Rotating

  • University of Hawaii School of Medicine

Residency

Internal Medicine

  • Beth Israel Medical Center
  • University of Hawaii School of Medicine

Fellowship

Critical Care Medicine

  • University of Missouri Kansas City

Pulmonary Medicine

  • University of Missouri Kansas City

Boards

American Board of IM - Pulmonary Disease
American Board of IM - Critical Care Medicine

Insurances

MU Health Care participates with most major managed care organizations. To find out whether MU Health Care is a participating provider in your insurance plan or network, or for information on co-payments and deductibles, please contact your insurance carrier directly.

Academic Information

Associate Professor of Medicine

Office

1 Hospital Drive
Columbia, MO 65212
United States

P. 573-882-2991
F. 573-884-1235

Research Interests

  • Asthma, critical care medicine
  • Pulmonary (lung) diseases
  • Respiratory disorders
  • Sleep disorders
  • Chronic obstructive pulmonary disease (COPD)
  • Pneumonia

Awards & Honors

  • Passed Pulmonary Medicine Board Examination. September 09, 2009.
  • "Top 30% Reviewer" for the Annals of Internal Medicine. 2008.
  • Poster Finalist Award for work entitled, "Incremental Cost-effectiveness of Combination Inhaler Therapy in Moderate to Severe COPD" at the International Society for Pharmacoeconomics and Outcome Research Annual Meeting in Toronto, Ontario, Canada from May 2-7, 2008.
  • Invited Ad Hoc Reviewer. British Medical Journal Point of Care Section. December 2007 - present.
  • Editor. Cochrane Airways Group. Cochrane Collaborations, UK

Professional Societies

  • Fellow, American College of Chest Physicians (2002-present)
  • Member, American College of Chest Physicians (1997-present)
  • Member, American Thoracic Society (1997-present)

Publications

  • Oba Y, Keeney E, Ghatehorde N, Dias S. Dual combination therapy versus long‐acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2018 December 03. DOI:10.1002/14651858.CD012620.pub2
  • Oba Y, Fadila M, Keeney E, Dias S. Fixed-dose combination inhalers compared to long-acting bronchodilators for COPD: a network meta-analysis (Protocol). Cochrane Database Syst Rev. 2017 March 29:CD012620. doi:10.1002/14651858.CD012620
  • Oba Y, Chandran A, Devasahayam J. Long-acting muscarinic antagonist versus inhaled corticosteroid when added to Long-acting β-agonist for COPD: a meta-analysis. COPD. 2016 May 5:1-9. [Epub ahead of print]
  • Oba Y, Sarva S, Dias S. Efficacy and safety of muscarinic antagonist-beta2 agonist bronchodilators: a network meta-analysis. Thorax. 2016 Jan;71(1):15-25. doi: 10.1136/thoraxjnl-2014-206732. Epub 2015 Oct 21.
  • Oba Y, Lone N. Comparative efficacy of long-acting muscarinic antagonists in preventing COPD exacerbations: a network meta-analysis and meta-regression. Ther Adv Respir Dis. 2015, Vol. 9(1) 3–15.
  • Oba Y, Lone N. Mortality benefit of vasopressor and inotropic agents in septic shock: A Bayesian network meta-analysis of randomized controlled trials. J Crit Care. 2014 Oct;29(5):706-10.
  • Oba Y, Lone N. Comparative efficacy of inhaled corticosteroid and long-acting beta agonist combinations in preventing COPD exacerbations: a Bayesian network meta-analysis. Int J Chron Obstruct Pulmon Dis 2014:9 469–479